F2RL2 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O00254 |
---|---|
Clone Names | 100311224 |
Gene ID | 2151 |
---|---|
Other Names | Proteinase-activated receptor 3, PAR-3, Coagulation factor II receptor-like 2, Thrombin receptor-like 2, F2RL2, PAR3 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | F2RL2 |
---|---|
Synonyms | PAR3 |
Function | Receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis. |
Cellular Location | Cell membrane; Multi-pass membrane protein. |
Tissue Location | Highest expression in the megakaryocytes of the bone marrow, lower in mature megakaryocytes, in platelets and in a variety of other tissues such as heart and gut |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Coagulation factor II (thrombin) receptor-like 2 (F2RL2)is a member of the large family of 7-transmembrane-region receptorsthat couple to guanosine-nucleotide-binding proteins. F2RL2 is alsoa member of the protease-activated receptor family and activated bythrombin. F2RL2 is activated by proteolytic cleavage of itsextracellular amino terminus. The new amino terminus functions as atethered ligand and activates the receptor. F2RL2 is a cofactor forF2RL3 activation by thrombin. It mediates thrombin-triggeredphosphoinositide hydrolysis and is expressed in a variety oftissues.
References
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Popovic, M., et al. J. Thromb. Thrombolysis 30(2):164-171(2010)Van Laer, L., et al. Eur. J. Hum. Genet. 18(6):685-693(2010)Wysoczynski, M., et al. Mol. Cancer Res. 8(5):677-690(2010)Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.